NEW YORK (GenomeWeb) – Following Cepheid's third quarter financial results, investment bank Canaccord Genuity today downgraded the molecular diagnostic firm's stock to a Hold rating.

Analyst Mark Massaro also lowered his price target on Cepheid's stock to $34 from $42. 

The changes come after Cepheid said that its Q4 revenues rose 10 percent year over year, but still fell short of the consensus Wall Street estimate. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.